SIC
AZN icon

SFE Investment Counsel’s AstraZeneca AZN Stock Holding History

SFE Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Hold
4,000
– – 0.39% 70
2026
Q1 		$1.37M Buy
+4,000
New +$771K 0.22% 84

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SFE Investment Counsel's AZN Position: Q2 2026 in Review

SFE Investment Counsel held its AstraZeneca (AZN) position steady in Q2 2026 at 3,826 shares worth $725K. The position accounts for 0.1% of the portfolio, ranked #101.

SFE Investment Counsel first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $755K in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • SFE Investment Counsel held 3,826 shares of AstraZeneca worth $725K as of Q2 2026.
  • SFE Investment Counsel left its AstraZeneca share count unchanged in Q2 2026.
  • AstraZeneca made up 0.1% of SFE Investment Counsel's portfolio in Q2 2026, its #101 holding.
  • SFE Investment Counsel first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
  • SFE Investment Counsel's AstraZeneca position peaked at $755K in Q1 2026.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on SFE Investment Counsel's 13F filing for Q2 2026, filed 5 Aug 2026.